QC Associate at Arcellx

Redwood City, California, United States

Arcellx Logo
Not SpecifiedCompensation
Entry Level & New Grad, Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Cell TherapyIndustries

Requirements

  • BS or MS in biological sciences or a related field
  • 3+ years of pharmaceutical or biotechnology industry experience, including experience in cell therapy or microbiology
  • Previous experience performing environmental monitoring in a cleanroom
  • Excellent written and oral communication skills

Responsibilities

  • Execute GMP-compliant environmental monitoring of cleanrooms by performing non-viable and viable particulate sampling on a routine basis
  • Perform growth promotion to qualify media
  • Contribute to reviewing SOPs, forms, and logbooks related to environmental monitoring and microbiological methods
  • Govern the upkeep, calibration, and preventive maintenance of lab equipment and instruments
  • Manage inventory of environmental monitoring samples, lab supplies, and materials
  • Support tracking and trending of QC data

Skills

GMP
environmental monitoring
cleanroom sampling
non-viable particulate sampling
viable particulate sampling
growth promotion
SOP review
lab equipment calibration
preventive maintenance
inventory management
QC data tracking
microbiological methods

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters
2014Year Founded
$194.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI